NBI-1117568-SCZ3029: Evaluation of NBI-1117568 in Inpatient Adults With Schizophrenia

This study is testing a new medication called NBI-1117568 for people with schizophrenia who are experiencing an acute episode (a relapse or worsening of symptoms) serious enough to require hospitalization. The goal is to assess whether this drug is effective and safe for treating active schizophrenia symptoms in an inpatient setting. **You may be eligible if...** - You have been diagnosed with schizophrenia - You are currently experiencing a relapse or worsening of symptoms and need to be hospitalized - You are willing and able to remain in an inpatient setting for the duration of the study - You are willing to stop other antipsychotic medications before participating **You may NOT be eligible if...** - You have a known allergy to any ingredient in NBI-1117568 - You have an unstable or poorly controlled medical condition or serious chronic illness - You are considered to be at risk of harming yourself or others - You have had moderate to severe substance use disorder (other than nicotine or caffeine) within the past 6 months - You tested positive for alcohol or other prohibited drugs at screening - You have a history of not following research protocols Talk to your doctor to see if this trial is right for you.